|
|
|
|
| LEADER |
02629nam a2200241 u 4500 |
| 001 |
EB002000631 |
| 003 |
EBX01000000000000001163532 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Acoustic radiation force impulse imaging for diagnosis and monitoring of liver fibrosis in patients with hepatitis C
|h Elektronische Ressource
|b a review of diagnostic accuracy, clinical effectiveness, cost-effectiveness, and guidelines
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 246 |
3 |
1 |
|a ARFI for the diagnosis and monitoring of liver fibrosis in patients with hepatitis C
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2016, 18 April 2016
|
| 300 |
|
|
|a 1 PDF file (32 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 500 |
|
|
|a Title from PDF caption. - "CADTH Rapid Response Service."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK362186
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Acoustic Radiation Force Imaging (ARFI) is an emerging non-invasive procedure that is a potential alternative to liver biopsy. One significant advantage of ARFI imaging is that it is integrated into a conventional ultrasonographic system. This also allows for a sonographic evaluation of the liver to be performed simultaneously with ARFI; this provides patients an ideal 'one-stop shop' for noninvasive liver evaluation, even in patients with a significant amount of ascites. ARFI is a technology designed to measure shear wavefront at multiple locations to calculate tissue stiffness. The wave velocity determines tissue stiffness through a simple method: the stiffer the tissue, the greater velocity. The purpose of this Rapid Response report is to review the clinical effectiveness, diagnostic accuracy, cost-effectiveness, and evidence-based guidelines regarding the use of ARFI for detecting and grading liver fibrosis in patients with hepatitis C. This report represents an update to a previous 2012 report that reviewed the clinical and cost-effectiveness evidence of diagnosis and monitoring of liver fibrosis among patients with hepatitis C; that report found moderate to high accuracy for FibroTest, transient elastography (known as FibroScan), and aminotransferase-to-platelet ratio index (APRI) with generally higher accuracy for cirrhosis compared with earlier fibrosis stages
|